| P2093 | author name string | Michele Marinò | |
| | Irene Campi | |
| | Guia Vannucchi | |
| | Ilaria Ionni | |
| | Giulia Lanzolla | |
| | Elisa Lazzaroni | |
| | Federica Sileo | |
| P2860 | cites work | Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis | Q21144329 |
| | HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection | Q24793685 |
| | Simvastatin induces caspase-independent apoptosis in LPS-activated RAW264.7 macrophage cells | Q40344237 |
| | Statin-modified dendritic cells regulate humoral immunity in experimental autoimmune myasthenia gravis | Q40603286 |
| | Risk Factors for Graves' Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. | Q40812821 |
| | Interactions between cell death induced by statins and 7-ketocholesterol in rabbit aorta smooth muscle cells | Q40884543 |
| | Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblasts | Q41959819 |
| | Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis | Q43109248 |
| | Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study | Q43198503 |
| | Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin | Q43233583 |
| | Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease | Q43758895 |
| | Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients | Q44015510 |
| | Statin use in patients with asthma: a nationwide population-based study | Q44374077 |
| | A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma | Q44772777 |
| | Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials. | Q44845976 |
| | Oral simvastatin treatment in relapsing-remitting multiple sclerosis | Q44897670 |
| | Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome | Q46665392 |
| | Main messages for primary care from the 2016 European Guidelines on cardiovascular disease prevention in clinical practice | Q47601717 |
| | Beneficial effect of atorvastatin-modified dendritic cells pulsed with myelin oligodendrocyte glycoprotein autoantigen on experimental autoimmune encephalomyelitis | Q47696666 |
| | SERUM HIGH CHOLESTEROL IS A NOVEL RISK FACTOR FOR GRAVES' ORBITOPATHY (GO): RESULTS OF A CROSS-SECTIONAL STUDY. | Q48515824 |
| | Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. | Q49360067 |
| | Rehabilitative orbital decompression for Graves' orbitopathy: results of a randomized clinical trial | Q49946639 |
| | Autophagy is involved in the initiation and progression of Graves' orbitopathy. | Q50451657 |
| | Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. | Q50933902 |
| | Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial | Q51652663 |
| | Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy? | Q53207209 |
| | Radioiodine-Associated Exacerbation of Graves' Orbitopathy in the Japanese Population: Randomized Prospective Study. | Q53510651 |
| | Molecular pathology of Muller's muscle in Graves' ophthalmopathy. | Q54624984 |
| | Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro | Q58071447 |
| | The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study | Q58109023 |
| | Corticosteroids for Graves’ Ophthalmopathy: Systematic Review and Meta-Analysis | Q60313273 |
| | PROAPOPTOTIC EFFECT OF ATORVASTATIN ON STIMULATED RABBIT SMOOTH MUSCLE CELLS | Q62029348 |
| | 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture | Q63684404 |
| | Effect of Abnormal Thyroid Function on the Severity of Graves' Ophthalmopathy | Q67657511 |
| | Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy | Q74010201 |
| | Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131 | Q84506454 |
| | Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities | Q86387770 |
| | Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center | Q86521875 |
| | Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy | Q86549348 |
| | Treatment of active corticosteroid-resistant graves' orbitopathy | Q87246219 |
| | Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study | Q89161351 |
| | Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy | Q90874186 |
| | Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy | Q91073029 |
| | Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy | Q91445468 |
| | Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and orbital fibroblasts from Graves' ophthalmopathy patients | Q92501730 |
| | MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials | Q28077018 |
| | A century of cholesterol and coronaries: from plaques to genes to statins | Q28080618 |
| | Selenium and the course of mild Graves' orbitopathy | Q28238021 |
| | Clinical features of Graves' ophthalmopathy in an incidence cohort | Q28275743 |
| | Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury - rescue by high-dose statin treatment | Q28535160 |
| | Self-eating and self-killing: crosstalk between autophagy and apoptosis | Q29617748 |
| | Statins as potential therapeutic agents in neuroinflammatory disorders | Q34213875 |
| | Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial | Q34275827 |
| | Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 |
| | Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors | Q34432988 |
| | Teprotumumab for Thyroid-Associated Ophthalmopathy. | Q34556184 |
| | Mevalonate pathway: a review of clinical and therapeutical implications | Q34623889 |
| | C-Reactive Protein: How Has JUPITER Impacted Clinical Practice? | Q34986430 |
| | Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: results from the Daunia Heart Failure Registry. | Q35028959 |
| | Statins and their potential targets in multiple sclerosis therapy | Q35537898 |
| | Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation | Q35828643 |
| | Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. | Q35830997 |
| | Anti-inflammatory effects of statins: clinical evidence and basic mechanisms | Q36337932 |
| | The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy | Q36811289 |
| | Immunomodulatory and anti-inflammatory activities of statins | Q37548486 |
| | Statins as emerging treatments for asthma and chronic obstructive pulmonary disease | Q37754865 |
| | Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity | Q37829150 |
| | Innate immune activation and thyroid autoimmunity. | Q37940271 |
| | Prevention of Graves' ophthalmopathy | Q38013219 |
| | Smoking and thyroid | Q38098569 |
| | Prevalence and natural history of Graves' orbitopathy in the XXI century | Q38099144 |
| | Role of genetic and non-genetic factors in the etiology of Graves' disease. | Q38271025 |
| | Total thyroid ablation in Graves' orbitopathy | Q38367695 |
| | Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study | Q38471162 |
| | Current Insights into the Pathogenesis of Graves' Ophthalmopathy | Q38585018 |
| | Medical Treatment of Graves' Orbitopathy | Q38585021 |
| | Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any). | Q38869637 |
| | Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease? | Q38963406 |
| | Involvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells | Q39627631 |
| | Effect of statins on the viability of macrophages and smooth muscle cells | Q39755580 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 933 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Frontiers in Endocrinology | Q27723680 |
| P1476 | title | Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy | |
| P478 | volume | 10 | |